Literature DB >> 23988090

Evaluation of patients with intracranial tumors and central diabetes insipidus.

Ali Varan1, Erman Atas, Burça Aydın, Bilgehan Yalçın, Canan Akyüz, Tezer Kutluk, Münevver Büyükpamukçu.   

Abstract

The aim of the study is to evaluate the etiologic and clinical characteristics, treatment regimens, and outcome of the patients with intracranial tumors presenting with central diabetes insipidus (DI). Sixty-nine patients with intracranial tumors presenting with central DI between 1972 and 2012 were retrospectively evaluated. Fifty-three out of 69 patients were included in the analysis. Male/female ratio was 1.52, median age was 7.6 years. Of 53 patients, 37 patients (69.8%) were diagnosed with Langerhans cell histiocytosis, 14 patients (26.4%) with germinoma, 1 (1.9%) with astrocytoma, and 1 (1.9%) with optic glioma. 10-year overall survival (OS) rate and disease-free survival rate for all patients were 91.7% and 52%. 10-year OS rate according to diagnostic criteria was 91% for Langerhans cell histiocytosis (LCH) cases, 79% for intracranial germinoma, which was statistically significant (P = .0001). Central DI may be very important clinical presentation of serious underlying disease in children. Intracranial tumors are the most frequent cause of DI. Most frequent diagnosis were LCH and germ cell tumors in our series.

Entities:  

Mesh:

Year:  2013        PMID: 23988090     DOI: 10.3109/08880018.2013.816984

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  2 in total

Review 1.  Diabetes insipidus: The other diabetes.

Authors:  Sanjay Kalra; Abdul Hamid Zargar; Sunil M Jain; Bipin Sethi; Subhankar Chowdhury; Awadhesh Kumar Singh; Nihal Thomas; A G Unnikrishnan; Piya Ballani Thakkar; Harshad Malve
Journal:  Indian J Endocrinol Metab       Date:  2016 Jan-Feb

2.  Pituitary Morphology and Function in 43 Children with Central Diabetes Insipidus.

Authors:  Wendong Liu; Limin Wang; Minghua Liu; Guimei Li
Journal:  Int J Endocrinol       Date:  2016-03-29       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.